Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Stomach bug linked to fatty liver? new study investigates

NCT ID NCT07128147

Knowledge-focused Sponsor: Assiut University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study will check 200 adults with metabolic fatty liver disease for Helicobacter pylori infection using a stool test. The goal is to find out how common H. pylori is in this group. If a link is confirmed, it may open the door to new ways to manage fatty liver disease by treating the stomach infection.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If this study finds a strong link, it could point toward a new way to manage fatty liver disease by treating H. pylori infection.
What could go wrong
This is an early observational study, not a treatment trial. It only measures how common H. pylori is in these patients, so it cannot prove that treating the infection helps the liver.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 200 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Sep 2026

An estimate. Start dates often move.

Expected to finish

Sep 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Patients, and their relatives, were invited to do screening for fatty liver by doing conventional abdominal ultrasound (US) by any member of the nutrition clinic team for assessment of liver echopattern.Patients with detected bright liver by US suggestive of fatty liver have undergone an evaluation for the BMI and tests to detect metabolic risk abnormalities.Diagnosis of MAFLD was made when a patient has BMI \>25 kg/m2, T2DM or at least two metabolic risk abnormalities.Our study will use either H.pylori stool antigen test (SAT), after stoppage of PPI and antibiotics two weeks before the test, as it cheap and easy, or diagnostic upper endoscopy with biopsy.

Ages

18 to 60 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * All patients aged \>18 years old. * Was diagnosed as MAFLD based on abdominal ultrasonography (US) or other imaging techniques. Exclusion Criteria: * Patients aged ≤18 years old. * Pregnancy. * Presence of malignancy. * Type I DM. * Patients with fatty liver who undergone bariatric surgeries. * Previous history of alcohol consumption, steroids, proton pump inhibitors, antibiotics, and contraceptive pills.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Helicobacter pylori infection metabolic dysfunction-associated fatty liver disease are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

metabolic dysfunction-associated steatotic liver disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Helicobacter pylori infection metabolic dysfunction-associated fatty liver disease

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  2. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

More trials for these conditions

Other studies related to the condition(s) this trial covers.